EP3641775
COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD OF CARE TREATMENT FOR HEMATOLOGIC CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
21.6.2018EP published:
6.12.2023EP application number:
18731845.6
EPO information:
European Patent Register
Max expiry date:
20.6.2038
Title in English:
COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD OF CARE TREATMENT FOR HEMATOLOGIC CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOFLanguage of the patent:
English
Timeline
Today
21.6.2018EP application
6.12.2023EP Publication
Owner
Name:
Les Laboratoires ServierAddress:
35, rue de Verdun, 92284 Suresnes Cedex, FR
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
WEI, AndrewAddress:
Surrey Hills Victoria 3127, AU
Name:
MOUJALLED, DoniaAddress:
Lalor Victoria 3075, AU
Name:
POMILIO, GiovannaAddress:
Pascoe Vale Victoria 3044, AU
Name:
GENESTE, OlivierAddress:
92500 Rueil-Malmaison, FR
Name:
MARAGNO, Ana-LeticiaAddress:
78290 Croissy-Sur-Seine, FR
Priority
Number:
201762523389 PDate:
22.6.2017Country:
US
Number:
17189550Date:
6.9.2017Country:
EP
Classification
Categories:
A61K 31/519, A61K 31/5377, A61K 31/55, A61P 35/00, A61K 45/06